BTBansidhar Tarai

Bansidhar Tarai

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Bansidhar Tarai has a total of 69 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Comprehensive Analysis of Etiological Agents and Drug Resistance Patterns in Ventilator-Associated Pneumonia

    by Harendra K. Thakur, Bansidhar Tarai, Aradhana Bhargava, Pankaj Soni, Anup Kumar Ojha, Sudhakar Kancharla, Prachetha Kolli, Gowtham Mandadapu, Manoj Kumar Jena

    Ventilator-associated pneumonia (VAP) develops in patients who stay on mechanical ventilation for more than 48 h. In the presence of causative pathogens, the patient develops clinical signs such as purulent tracheal discharge, fever, and respiratory distress. A prospective observational study was carried out in the Intensive Care Unit (ICU) of Max Healthcare Centre, New Delhi, from 2020 to 2023. The study comprised 70 samples from patients diagnosed with VAP. This study thoroughly examined VAP-associated microorganisms and resistance in the hospital ICU. Klebsiella pneumoniae, Acinetobacter baumannii, and Pseudomonas aeruginosa were the most commonly reported pathogens. Significant drug resistance was seen in P. aeruginosa, K. pneumoniae, A. baumannii and Staphylococcus aureus. The heatmap also supported the antibiotic resistance data patterns obtained from conventional and automated systems of determination. Notably, Serratia marcescens, Escherichia coli, Klebsiella pneumoniae, Ralstonia insidiosa, and Ralstonia mannitolilytica, showed 60 to 100% of resistance to a number of antibiotics. Among all VAP patients, 31.42% early-onset and 68.57% late-onset VAP cases were detected. Out of 70 patients, 43 patients died (mortality rate 61.4%); majority of them suffered from late-onset VAP. The study goal was to describe the antibiotic resistance patterns and microbial ecology of the pathogens that were isolated from VAP patients. According to the heatmap analysis, a varied VAP microbiome with high prevalences of MDR in A. baumannii, P. aeruginosa, K. pneumoniae, and S. aureus was identified. To address the increasing prevalence of MDR VAP, the study highlights the critical need for improved VAP monitoring, strong infection control, and appropriate antibiotic usage.


  • Open Access

    Evaluating the Efficacy of a Polymerase Chain Reaction Assay for Pneumocystis carinii Detection in Respiratory Samples

    by Sonu Kumari Agarwal, Harendra Kumar Thakur, Bansidhar Tarai

    Introduction: Accurately identifying patients with pneumocystis pneumonia (PCP) presents considerable challenges, primarily relying on clinical suspicion. The manifestations of PCP lack specificity, encompassing symptoms such as cough, dyspnoea, fever, hypoxaemia, malaise and weight loss. Therefore, this study assesses the efficacy of a polymerase chain reaction (PCR) assay intended for use in clinical microbiology laboratories for the identification of Pneumocystis carinii from respiratory specimens. Materials and Methods: In this retrospective study, the medical records of patients aged 18 years and above were examined, focusing on those assessed using pneumocystis PCR-based tests. The study spanned from 2019 to 2022 in our tertiary care centre at Max Hospital, Saket. In this study, sputum and bronchoalveolar lavage (BAL) samples were proceeded for both staining and PCR for multi-copy mtLSU gene and single-copy dihydropteroate synthase polymorphisms (DHPS) fas gene of P. jirovecii. Results: In the analysis of 112 BAL specimens, 17 were identified as positive for P. carinii through both Grocott-Gomori’s Methenamine Silver Staining (GMS) staining and PCR. In addition, two BAL specimens were negative through GMS staining but showed positive results with PCR. On reviewing the clinical details of the patients associated with these two specimens, it was discovered that both individuals were under systemic steroid treatment, yet neither exhibited clinical signs of pneumocystis pneumonia (PCP). Consequently, these instances were classified as false positives by PCR. In comparison to GMS, the PCR assay demonstrated a sensitivity of 100% and specificity of 98% for detecting P. carinii in BAL specimens. Conclusions: The study underscores the necessity for individualised approaches, with each laboratory assessing the positive and negative predictive values based on their specific prevalence rates. In the ongoing pursuit of improving PCP diagnosis, PCR emerges as a promising screening tool that when used judiciously in conjunction with confirmatory measures, can enhance diagnostic precision in immunosuppressed populations.

  • Open Access

    Diagnosis of Ventilator-Associated Pneumonia – A Systematic Review and Meta-analysis of Laboratory Techniques

    by Harendra K. Thakur, Bansidhar Tarai, Aradhana Bhargava, Sonu K. Agarwal, Pankaj Soni, Sudhakar Kancharla, Prachetha Kolli, Gowtham Mandadapu, Manoj Kumar Jena

    Hospitalized patients on mechanical ventilation are at high-risk of developing ventilator-associated pneumonia (VAP), making early and accurate diagnosis essential for the best possible treatment outcomes. This review examined various laboratory techniques, such as aerobic cultures, Gram’s stain, and molecular techniques, to assess how well they diagnose VAP. We have done search strategies using Google Scholar, Medline Complete, and PubMed. Extensive statistical tools were utilized to examine studies and evaluate the diagnostic accuracy of laboratory results. Multiplex PCR was superior to Gram’s stain and culture methods in terms of sensitivity (92%) and specificity (86%). On the other hand, Gram’s stain showed the highest specificity (78.9%) and the lowest sensitivity (74.6%). The results of semi-quantitative, quantitative, enrichment culture showed a lower specificity (75.97%) but a moderate sensitivity (78.5%). The most accurate diagnostic approach for VAP, according to a meta-analysis, was multiplex PCR-based testing, closely followed by culture methods. Beyond separate tests, multiplex PCR, culture, and Gram’s stain combination increased sensitivity. Prompt and precise VAP diagnosis is essential for efficient treatment. With possible improvements through combination diagnostic techniques, multiplex PCR remains the most accurate diagnostic tool. However, more investigation is necessary to improve and certify VAP diagnostic instruments.


  • Reduction of Colonizer and Contaminated Blood Culture in Emergency

    by Bansidhar Tarai, Tongbram Geetarani Devi, Promila Kajla, Meenu Joseph, Namgyal Dolma, Smitha Manoj

    Contamination of blood cultures can lead to diagnostic confusion and increased healthcare costs due to unnecessary treatments and tests. Various techniques have been explored to reduce contamination rates, addressing the challenge of distinguishing true pathogens from contaminants. This study offers an overview of blood culture contamination, examining different approaches for enhancing both detection and prevention. It emphasizes the need for multidisciplinary collaboration and diverse strategies to enhance the accuracy and quality of blood culture sampling. Initiatives to improve infection control practices aim to ensure patient safety and achieve better outcomes. An observed increase in blood culture contamination rates in the Emergency department prompted our efforts to scientifically improve sampling methods and decrease colonizer blood culture reports.

  • Prevalence of Orofacial Mucormycosis in Coronavirus Disease-2019 Patients: Insights from a Tertiary Care Center in Northern India

    by Bansidhar Tarai, Harinder Kumar, Sonu Kumari Agrawal, Poornima Sen, Romila Bhan

    Introduction: The severe acute respiratory syndrome coronavirus 2 that is the cause of the coronavirus disease-2019 (COVID-19) pandemic is linked to a variety of opportunistic bacterial and fungal coinfections. Orofacial mycoses, fungal infections affecting the oral and facial regions, have recently gained attention as potential complications in individuals with COVID-19. Materials and Methods: This study aims to contribute to the understanding of orofacial mucormycosis in the context of COVID-19, particularly focusing on the prevalence among patients in a tertiary care center in Northern India. This study comprised respiratory materials from 255 COVID-19 patients treated at Max Hospital, Saket. The laboratory received specimens for microbiological pneumonia workup culture and molecular detection. Results: The most prevalent site for mucormycosis was the rhino-orbital region, accounting for a majority of cases at 58.2%. Following the rhino-orbital region, the involvement extended to the rhino-orbital-cerebral region in a notable proportion of cases. Pulmonary sites were identified as a significant location for mucormycosis, though less frequent compared to the rhino-orbital region. Mucormycosis diagnoses were predominantly made using direct microscopy, with 82.6% (196/255) of patients undergoing this diagnostic method. Conclusion: Our study in Northern India revealed a high prevalence of orofacial mucormycosis in middle-aged diabetic males, often with a history of COVID-19 hospitalization and steroid use. Rhizopus spp. were the most common Mucorales identified, with treatment challenges due to antifungal resistance. Molecular tests, such as matrix-assisted laser desorption ionization–time of flight, are valuable for species identification, emphasizing the need for heightened awareness during the COVID-19 pandemic.

  • Open Access

    Pathogenesis, Diagnosis and Therapeutic Strategies for Ventilator-associated Pneumonia

    by Harendra Kumar Thakur, Bansidhar Tarai, Aradhana Bhargava, Pankaj Soni, Prasana Kumar Rath, Bidyut Prava Mishra, Manoj Kumar Jena

    Ventilator-associated pneumonia (VAP) is a major health care associated infection which usually emanates from aspiration, immigration of pathogens from aerodigestive tract, adulterated appliance uses or medications. The mortality rate due to VAP is approximately 13% and the causative organisms are bacteria, viruses, and fungi. Many studies have investigated the causative organisms as Pseudomonas spp., Acinetobacter spp., Escherichia coli, Klebsiella pneumoniae, and Staphylococcus aureus with varying prevalence. Intensive Care Unit (ICU) admitted patients who are ventilated, are more prone to the infections where the pathogens adhere to the mucosa of lower respiratory tract of mechanically ventilated patients and start infections. Clinical diagnosis based on Clinical Pulmonary Infection Score (CPIS) has poor specificity and microbiological findings takes 48-72 hrs, that can delay the treatment of patients. Lymphopenia on complete blood count is a predictor of mortality in VAP patients, but decreased lymphocyte count occurs in various other infections too. Multiplex PCR is a better diagnostic technique for VAP which can even diagnose atypical bacteria along with other etiological agents. Effectively employing sampling techniques is a vital step in the diagnosis of VAP, enabling the identification of pathogens responsible for lung infections. Furthermore, the emergence of novel therapeutic options approved by regulatory bodies, adds significant advancements in VAP treatment. In this review article, we have performed an in-depth study on the pathogenesis, diagnosis and therapeutic strategies involved in VAP. This study will help the researchers working in this area to design their work appropriately with the updated knowledge on VAP.


  • Open Access

    A Prospective, Observational and Comparative Study of In-Vitro Susceptibility of Isepamicin against Clinical Isolates from Various Clinical Sources (Triple I Study - Isepamicin in India)

    by Niraj Tyagi, Abdul Ansari, Bhaskar Narayan Chaudhuri, Bansidhar Tarai, Ami Varaiya, Aarthi Sundaresan

    Objectives: This study aims to investigate the in-vitro susceptibility of clinical isolates against Isepamicin and compared it with Gentamicin and Amikacin. Patients and Methods: In this multicentre prospective study, clinical specimens of patients were collected from three different regions of India. Clinical isolates from urine, intra-abdominal, broncho-alveolar lavage, endotracheal secretion, and sterile blood were included. The E-test was used to quantify the minimal inhibitory concentration (MIC) for Isepamicin, Gentamicin, and Amikacin. The percentages of bacterial isolates were categorized as susceptible, intermediate, and resistant according to the European Committee on Antimicrobial Susceptibility Testing (EUCAST) guidelines as per Comité de l'Antibiogramme de la Société Française de Microbiologie (CA-SFM) recommendation. Results: A total of 8 different bacterial isolates were collected from 150 clinical samples obtained from 50 patients. Respiratory (63 [42%]) and urine (44 [29.3%]) specimens were the most common sources for bacterial strains. The most identified bacterial isolates were K. pneumoniae (40 [26.6%]) and P. aeruginosa (38 [25%]). Isepamicin was found to be highly effective in urine samples and showed excellent sensitivity against E. coli (93.3%), followed by P. aeruginosa (57.9%) and K. pneumoniae (55.0%). Antimicrobial sensitivity was highest for Isepamicin (60/108 [56%]) at MIC≤1 mg/L and was most effective against Gram-negative bacterial isolates from the intensive care units (ICUs). Conclusions: Isepamicin could treat E. coli infections and could be an effective therapy in the treatment of urinary tract infections (UTIs). Moreover, it could also be used as an alternative to Gentamicin and Amikacin against resistant cases. Keywords: Aminoglycosides, Amikacin, E. coli, Gentamicin, Gram-negative bacteria, Isepamicin.

  • Open Access

    Efficacy and safety of SARS-CoV-2 vaccines in living donor liver transplant recipients

    by Shekhar Singh Jadaun, Phani Deepti Jakkilinki, Ana Hasnain, Bansi Dhar Tarai, Dhiraj Agrawal, Shweta Singh, Shaleen Agarwal, Subhash Gupta, Sanjiv Saigal


  • Syndromic approach to SARS-CoV-2 detection using QIAstat-Dx SARS-CoV-2 panel from clinical samples

    by Akshita Gupta, Anushika Soni, Sheetalnath Rooge, Diptanu Paul, Reshu Agarwal, Bansidhar Tarai, Ekta Gupta